End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
Identifieur interne : 000E65 ( Istex/Corpus ); précédent : 000E64; suivant : 000E66End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
Auteurs : Nicolas Simon ; Joëlle Micallef ; Jean-Charles Reynier ; Monique Lesourd ; Tatiana Witjas ; André Alicherif ; Jean-Philippe Azulay ; Olivier BlinSource :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
English descriptors
- KwdEn :
Abstract
This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20400
Links to Exploration step
ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Reynier, Jean Harles" sort="Reynier, Jean Harles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Azulay, Jean Hilippe" sort="Azulay, Jean Hilippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation><affiliation><mods:affiliation>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20400</idno><idno type="url">https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E65</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Reynier, Jean Harles" sort="Reynier, Jean Harles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Azulay, Jean Hilippe" sort="Azulay, Jean Hilippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><affiliation><mods:affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</mods:affiliation></affiliation><affiliation><mods:affiliation>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07">2005-07</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="803">803</biblScope><biblScope unit="page" to="809">809</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8D53D2A4341B0E12C30A815D20DEA8852D6955B3</idno><idno type="DOI">10.1002/mds.20400</idno><idno type="ArticleID">MDS20400</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>akinesia</term><term>intravenous</term><term>pharmacokinetics/pharmacodynamics</term><term>piribedil</term><term>randomized double‐blind study</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Nicolas Simon MD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</json:string></affiliations></json:item><json:item><name>Joëlle Micallef MD, PhD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string></affiliations></json:item><json:item><name>Jean‐Charles Reynier MD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string></affiliations></json:item><json:item><name>Monique Lesourd MD</name><affiliations><json:string>Institut de Recherches Internationales Servier, Courbevoie, France</json:string></affiliations></json:item><json:item><name>Tatiana Witjas MD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string></affiliations></json:item><json:item><name>André Alicherif MD, PhD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string></affiliations></json:item><json:item><name>Jean‐Philippe Azulay MD, PhD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string></affiliations></json:item><json:item><name>Olivier Blin MD, PhD</name><affiliations><json:string>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</json:string><json:string>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>randomized double‐blind study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>akinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>piribedil</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>intravenous</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pharmacokinetics/pharmacodynamics</value></json:item></subject><articleId><json:string>MDS20400</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>5.979</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1127</abstractCharCount><pdfWordCount>3855</pdfWordCount><pdfCharCount>24260</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>177</abstractWordCount></qualityIndicators><title>End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><refBibs><json:item><author><json:item><name>MJ Millan</name></json:item><json:item><name>L Maiofiss</name></json:item><json:item><name>D Cussac</name></json:item><json:item><name>V Audinot</name></json:item><json:item><name>JA Boutin</name></json:item><json:item><name>A Newman‐Tancredi</name></json:item></author><host><volume>303</volume><pages><last>804</last><first>791</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Differential profile of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes</title></json:item><json:item><author><json:item><name>A Newman‐Tancredi</name></json:item><json:item><name>D Cussac</name></json:item><json:item><name>V Audinot</name></json:item></author><host><volume>303</volume><pages><last>814</last><first>805</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Differential actions of antiparkinson agents at multiple classes of monoaminergic receptors. II. Agonist and antagonist properties at subtypes of dopamine D2‐like receptor and α1/ α2‐adrenoreceptor</title></json:item><json:item><author><json:item><name>MJ Millan</name></json:item><json:item><name>D Cussac</name></json:item><json:item><name>G Milligan</name></json:item></author><host><volume>297</volume><pages><last>887</last><first>876</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human α2‐adrenoreceptors: cellular and functional characterization</title></json:item><json:item><author><json:item><name>P Jenner</name></json:item></author><host><volume>239</volume><pages><last>8</last><first>2</first></pages><issue>Suppl.</issue><author></author><title>J Neurol</title></host><title>Parkinson's disease: pathological mechanisms and acceptance of piribedil</title></json:item><json:item><author><json:item><name>L Smith</name></json:item><json:item><name>M De Salvia</name></json:item><json:item><name>P Jenner</name></json:item><json:item><name>CD Marsden</name></json:item></author><host><volume>11</volume><pages><last>135</last><first>125</first></pages><author></author><title>Mov Disord</title></host><title>An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,4‐tetrahydropyridine‐treated common marmosets</title></json:item><json:item><author><json:item><name>P Rondot</name></json:item><json:item><name>M Ziegler</name></json:item></author><host><volume>239</volume><pages><last>34</last><first>28</first></pages><issue>Suppl.</issue><author></author><title>J Neurol</title></host><title>Activity and acceptability of Trivastal in Parkinson's disease: a multicenter study</title></json:item><json:item><author><json:item><name>H Kwiecinski</name></json:item><json:item><name>N Fedorova</name></json:item><json:item><name>A Takats</name></json:item><json:item><name>E Ruzicka</name></json:item><json:item><name>Z Jamrozik</name></json:item><json:item><name>S Del Signore</name></json:item></author><host><volume>58</volume><pages><first>163</first></pages><issue>Suppl.</issue><author></author><title>Neurology</title></host><title>A multicenter trial of piribedil as early adjunct treatment for Parkinson's disease: piribedil international study group</title></json:item><json:item><author><json:item><name>M Ziegler</name></json:item><json:item><name>A Castro‐Caldas</name></json:item><json:item><name>S Del Signore</name></json:item></author><host><volume>7</volume><pages><last>133</last><first>1</first></pages><issue>Suppl.</issue><author></author><title>Parkinsonism Relat Disord</title></host><title>Efficacy of piribedil in akinetic‐hypertonic Parkinsonian patients after 4‐month combination treatment with L‐dopa</title></json:item><json:item><author><json:item><name>C Chezaubernard</name></json:item><json:item><name>P Klippert</name></json:item><json:item><name>JP Jeanniot</name></json:item><json:item><name>L Grislain</name></json:item><json:item><name>A Papalexiou</name></json:item></author><host><pages><last>25</last><first>21</first></pages><issue>French edition: special issue</issue><author></author><title>JAMA</title></host><title>Piribedil: nouvelles donnees de pharmacocinetique et de metabolisme chez l'homme</title></json:item><json:item><author><json:item><name>M Ziegler</name></json:item><json:item><name>U Spampinato</name></json:item><json:item><name>P Rondot</name></json:item></author><host><pages><last>30</last><first>26</first></pages><issue>French edition: special issue</issue><author></author><title>JAMA</title></host><title>Cinetique plasmatique du piribedil par voie intraveineuse et correlation avec le tremblement parkinsonien</title></json:item><json:item><author><json:item><name>N Shetty</name></json:item><json:item><name>JH Friedman</name></json:item><json:item><name>K Kieburtz</name></json:item><json:item><name>FJ Marshall</name></json:item><json:item><name>D Oakes</name></json:item><json:item><name> </name></json:item></author><host><volume>22</volume><pages><last>212</last><first>207</first></pages><author></author><title>Clin Neuropharmacol</title></host><title>The placebo response in Parkinson's disease</title></json:item><json:item><author><json:item><name>O Rascol</name></json:item><json:item><name>O Blin</name></json:item><json:item><name>C Thalamas</name></json:item></author><host><volume>45</volume><pages><last>741</last><first>736</first></pages><author></author><title>Ann Neurol</title></host><title>ABT‐431, a D1 receptor agonist pro‐drug has efficacy in Parkinson's disease</title></json:item><json:item><host><author></author><title>Unified Parkinson's Disease Rating Scale</title></host></json:item><json:item><author><json:item><name>M Ziegler</name></json:item><json:item><name>S Del Signore</name></json:item><json:item><name>C Bonhomme</name></json:item><json:item><name>U Spampinato</name></json:item></author><host><volume>7</volume><pages><first>257</first></pages><issue>Suppl</issue><author></author><title>Parkinsonism Relat Disord</title></host><title>Resting tremor is inversely related to piribedil plasma concentration after intravenous administration in parkinsonian patients</title></json:item><json:item><author><json:item><name>J Hubble</name></json:item></author><host><volume>58</volume><pages><last>50</last><first>42</first></pages><issue>Suppl.</issue><author></author><title>Neurology</title></host><title>Long‐term studies of dopamine agonists</title></json:item><json:item><author><json:item><name>T Van Laar</name></json:item><json:item><name>R Van der Geest</name></json:item><json:item><name>M Danhof</name></json:item><json:item><name>HE Bodde</name></json:item><json:item><name>PH Goossens</name></json:item><json:item><name>RA Roos</name></json:item></author><host><volume>21</volume><pages><last>158</last><first>152</first></pages><author></author><title>Clin Neuropharmacol</title></host><title>Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>VP Calabrese</name></json:item><json:item><name>KA Lloyd</name></json:item><json:item><name>P Brancazio</name></json:item></author><host><volume>13</volume><pages><last>774</last><first>768</first></pages><author></author><title>Mov Disord</title></host><title>N‐0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism</title></json:item><json:item><author><json:item><name>S Ruggieri</name></json:item><json:item><name>F Stocchi</name></json:item><json:item><name>A Carta</name></json:item></author><host><volume>3</volume><pages><last>319</last><first>313</first></pages><author></author><title>Mov Disord</title></host><title>Comparison between L‐dopa and lisuride intravenous infusions: a clinical study</title></json:item><json:item><author><json:item><name>R De la Fuente‐Fernandez</name></json:item><json:item><name>TJ Ruth</name></json:item><json:item><name>V Sossi</name></json:item><json:item><name>M Schultzer</name></json:item><json:item><name>DB Calne</name></json:item><json:item><name>AJ Stoessl</name></json:item></author><host><volume>293</volume><pages><last>1166</last><first>1164</first></pages><author></author><title>Science</title></host><title>Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease</title></json:item><json:item><author><json:item><name>R De la Fuente‐Fernandez</name></json:item><json:item><name>AJ Stoessl</name></json:item></author><host><volume>25</volume><pages><last>306</last><first>302</first></pages><author></author><title>Trends Neurosci</title></host><title>The placebo effect in Parkinson's disease</title></json:item><json:item><author><json:item><name>N Simon</name></json:item><json:item><name>N Frey</name></json:item><json:item><name>J Micallef</name></json:item><json:item><name>JC Reynier</name></json:item><json:item><name>M Lesourd</name></json:item><json:item><name>T Witjas</name></json:item></author><host><volume>17</volume><pages><first>86</first></pages><issue>Suppl. 5</issue><author></author><title>Mov Disord</title></host><title>A pharmacokinetic/pharmacodynamic study on akinesia following a single intravenous infusion of piribedil in Parkinson's disease patients</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>20</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>809</last><first>803</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20400</json:string></doi><id>8D53D2A4341B0E12C30A815D20DEA8852D6955B3</id><score>0.161765</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2005 Movement Disorder Society</p></availability><date>2005</date></publicationStmt><notesStmt><note type="content">*Presented at the annual meeting of the Movement Disorder Society, November 2002.</note><note>IRIS (Institut de Recherches Internationales Servier), Courbevoie France</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><author xml:id="author-1"><persName><forename type="first">Nicolas</forename><surname>Simon</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Joëlle</forename><surname>Micallef</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Jean‐Charles</forename><surname>Reynier</surname></persName><roleName type="degree">MD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Monique</forename><surname>Lesourd</surname></persName><roleName type="degree">MD</roleName><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Tatiana</forename><surname>Witjas</surname></persName><roleName type="degree">MD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">André</forename><surname>Alicherif</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Jean‐Philippe</forename><surname>Azulay</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">Olivier</forename><surname>Blin</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><affiliation>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07"></date><biblScope unit="volume">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="803">803</biblScope><biblScope unit="page" to="809">809</biblScope></imprint></monogr><idno type="istex">8D53D2A4341B0E12C30A815D20DEA8852D6955B3</idno><idno type="DOI">10.1002/mds.20400</idno><idno type="ArticleID">MDS20400</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>randomized double‐blind study</term></item><item><term>Parkinson's disease</term></item><item><term>akinesia</term></item><item><term>piribedil</term></item><item><term>intravenous</term></item><item><term>pharmacokinetics/pharmacodynamics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-05-27">Received</change><change when="2004-08-15">Registration</change><change when="2005-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v20:7</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2005-07">July 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20400</doi><idGroup><id type="unit" value="MDS20400"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-05-27"></event><event type="manuscriptRevised" date="2004-07-30"></event><event type="manuscriptAccepted" date="2004-08-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-02-22"></event><event type="firstOnline" date="2005-02-22"></event><event type="publishedOnlineFinalForm" date="2005-07-05"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">803</numbering><numbering type="pageLast">809</numbering></numberingGroup><correspondenceTo>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20400.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="21"></count><count type="wordTotal" number="4334"></count></countGroup><titleGroup><title type="main" xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study<link href="#fn1"></link></title><title type="short" xml:lang="en">Effect of Piribedil on Akinesia in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nicolas</givenNames><familyName>Simon</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Joëlle</givenNames><familyName>Micallef</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jean‐Charles</givenNames><familyName>Reynier</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Monique</givenNames><familyName>Lesourd</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Tatiana</givenNames><familyName>Witjas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>André</givenNames><familyName>Alicherif</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jean‐Philippe</givenNames><familyName>Azulay</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Olivier</givenNames><familyName>Blin</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="olivier.blin@mail.ap-hm.fr">olivier.blin@mail.ap‐hm.fr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Institut de Recherches Internationales Servier, Courbevoie, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">randomized double‐blind study</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">akinesia</keyword><keyword xml:id="kwd4">piribedil</keyword><keyword xml:id="kwd5">intravenous</keyword><keyword xml:id="kwd6">pharmacokinetics/pharmacodynamics</keyword></keywordGroup><fundingInfo><fundingAgency>IRIS (Institut de Recherches Internationales Servier), Courbevoie France</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from <i>off</i> to <i>on</i> state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing <i>off</i> state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from <i>off</i>→<i>on</i>. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Presented at the annual meeting of the <i>Movement</i> Disorder Society, November 2002.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Effect of Piribedil on Akinesia in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title></titleInfo><name type="personal"><namePart type="given">Nicolas</namePart><namePart type="family">Simon</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joëlle</namePart><namePart type="family">Micallef</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Charles</namePart><namePart type="family">Reynier</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Monique</namePart><namePart type="family">Lesourd</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tatiana</namePart><namePart type="family">Witjas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">André</namePart><namePart type="family">Alicherif</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Philippe</namePart><namePart type="family">Azulay</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Blin</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille, France</affiliation><affiliation>CPCET, CHU Timone, 264 rue St. Pierre, 13385 Marseille Cedex 5, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-07</dateIssued><dateCaptured encoding="w3cdtf">2004-05-27</dateCaptured><dateValid encoding="w3cdtf">2004-08-15</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">2</extent><extent unit="references">21</extent><extent unit="words">4334</extent></physicalDescription><abstract lang="en">This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</abstract><note type="content">*Presented at the annual meeting of the Movement Disorder Society, November 2002.</note><note type="funding">IRIS (Institut de Recherches Internationales Servier), Courbevoie France</note><subject lang="en"><genre>keywords</genre><topic>randomized double‐blind study</topic><topic>Parkinson's disease</topic><topic>akinesia</topic><topic>piribedil</topic><topic>intravenous</topic><topic>pharmacokinetics/pharmacodynamics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>803</start><end>809</end><total>7</total></extent></part></relatedItem><identifier type="istex">8D53D2A4341B0E12C30A815D20DEA8852D6955B3</identifier><identifier type="DOI">10.1002/mds.20400</identifier><identifier type="ArticleID">MDS20400</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3
|texte= End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
}}
| This area was generated with Dilib version V0.6.29. |  |